Therapy Areas: Inflammatory Diseases
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
7 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of Verona Pharma plc (Nasda...
Avobis Bio's AVB-114 implantable cell therapy granted US FDA RMAT designation for Crohn's perianal fistulas
6 October 2025 - Avobis Bio LLC, a US-based clinical stage company developing implantable cell therapies, announced Friday that the US Food and Drug Administration (FDA) has granted Regenerative Medic...
Celltrion launches AVTOZMA IV in the United States following FDA approval
2 October 2025 - South Korea-based Celltrion, Inc., a global biopharmaceutical company, announced on Thursday that it has launched AVTOZMA (CT-P47, tocilizumab-anoh) intravenous formulation in the Uni...
Novartis to launch US direct-to-patient platform for Cosentyx
30 September 2025 - Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) announced on Monday that it plans to launch a direct-to-patient (DTP) platform in the United States which will...
Vascarta completes VAS-101 osteoarthritis clinical trial
30 September 2025 - Vascarta Inc, a clinical-stage biopharmaceutical company focused on innovative treatments for pain and inflammation, announced on Monday the successful completion of its phase 1 cl...
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
29 September 2025 - Anti-inflammatory therapeutics developer Sen-Jam Pharmaceutical announced on Friday that, in collaboration with pharmaceutical manufacturer KVK Tech, it has completed the final dev...